NCT06698549View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

July 21, 2025

Study Completion Date

July 21, 2025

Conditions
COVID 19
Interventions
DRUG

ALG-097558

Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami, Miami

33603

Genesis Clinical Trials, Tampa

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Aligos Therapeutics

INDUSTRY

NCT06698549 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function | Biotech Hunter | Biotech Hunter